Pharma Phighting Back?
With the release of Michael Moore’s new film attacking the American healthcare system looming, it seems that “Big Pharma” has joined the blogging fray just in time, adding a new avenue of communications to their arsenal on the eve of taking a potential PR hit.
Notably, pharmaceutical giants GlaxoSmithKline and Johnson&Johnson have each launched corporate blogs recently, with J&J focusing on a company-wide site, while GSK launched a product-specific blog.
Pharmaceutical industry blog Pharmalot commented on the developments over the weekend, noting that Big Pharma appears to want to use blogs to answer to critics and shape the conversation—but under tightly controlled circumstances. Is that really conversation at all, they wonder?
[…]And so the onslaught has begun. Big pharma is embracing the blog concept in order to shape and, if necessary, counteract the discussion about its activities and products. Of course, these are tightly controlled and so the content and comments are more than likely to restrict the scope of conversation.
Interesting take on it, especially when you give a close read to GSK’s blog, which is focused entirely on their new weight-loss drug, Alli. In one particular post, for example, there are several comments from members of the focus group that completed a trial of the drug…and they read a little like talking points to my cynical suspicious eyes.
So the question, which has some ties to the ongoing debate over ghostblogging, is whether it’s “okay” for a blog to be used simply as a PR tool (if that’s indeed what GSK or J&J are doing with their new blogging efforts—I believe it is too early to judge).
Does it have to be a true, authentic conversation or does using a blog to spread or control a message have some merit? In the Topaz Partners podcast last week, Todd Van Hoosear attempted to settle this question of ghostblogging by arguing that companies using blogs as a publicity tool rather than a true addition to the social media conversation should simply refrain from referring to such sites as “blogs.”
I will be monitoring with interest, as should the companies behind them, these new blogs—and the social media landscape’s reaction to them.
Technorati tags: Michael Moore; Pharma; Topaz Partners; VanHoosear; ghostblogging

2 Comments to "Pharma Phighting Back?"
Ryan O'Rourke
June 21, 2007
Rocky
June 21, 2007